OpenFold AI Research Consortium welcomes 4 new members: Bayer, Dassault, CHARM Therapeutics and BaseCamp Research


DAVIS, CA–()–openfold, a non-profit artificial intelligence (AI) research consortium dedicated to developing free and open source software tools for biology and drug discovery, today announced the addition of four new industry members: Bayer, Dassault Systèmes, CHARM Therapeutics and BaseCamp Research Ltd.

OpenFold, a consortium of university and industry partners founded in February 2022, is a project of Open Molecular Software Foundation, a non-profit organization dedicated to advancing the molecular sciences by building communities for the development of open-source research software. The four new members join the founders of OpenFold: Mohammed AlQuraishi’s laboratory, Cyrus biotechnology, Arzeda, Pass Bio and Forward-thinking design by Genentech.

Bayer from Leverkusen, Germany, is a global company with core competencies in the life science areas of health and nutrition. Dassault Systems SEfrom Velizy-Villacoublay, France, develops software for creating virtual 3D environments for product design, simulation and manufacturing. CHARM Therapeutics from London applies 3D deep learning technology to drug discovery and development. BaseCamp Ltd of London has created Knowledge Graph, a database of proteins from previously undiscovered organisms found in various natural environments for the development of new medicines, diagnostics and agricultural products.

“This membership growth continues the momentum following the formation of the consortium as well as the launch of the consortium’s first published AI model for protein structure prediction, performed in the lab of Dr. Mohammed AlQuraishi, both this June,” said Brian Weitzner, Ph.D. Outpace Bios Associate Director of Computational and Structural Biology and co-founder of OpenFold.

“At Bayer, we drive innovation and transformation. We are excited to partner with OpenFold, where we can collaborate with leading experts across industries to develop best practices for pharmaceutical and agricultural product design. By computationally simplifying our discovery process, we can increase the speed and quality of product design,” said Dr. Ruth Wagner, VP, Head of Plant Biotechnology Data Science & Analytics at Bayer’s Crop Science Division.

“By joining the growing OpenFold community, we are excited to strengthen the use of AI in our discovery solution experiences.” Reza Sadeghi, Chief Strategy Officer BIOVIA, Dassault Systèmes.

OpenFold’s mission is to make the most powerful software ever developed – AI systems with the ability to construct the molecules of life – available to everyone. These tools can be used by academics, biotech and pharmaceutical companies, or students learning to design tomorrow’s medicines, accelerate basic biology research, and bring new cures to market that would be undetectable without AI.

About OpenFold

OpenFold is a non-profit artificial intelligence (AI) research consortium of academic and industry partners whose goal is to develop free and open source software tools for biology and drug discovery, hosted as a project of the Open Molecular Software Foundation. Membership is recommended by biotech, pharmaceutical, synthetic bio, software/tech, and nonprofit research organizations. For more information, please visit: OpenFold Consortium.

Join OpenFold

Press and membership inquiries should be sent to [email protected]


Comments are closed.